SSY GROUP (02005) has announced that the group has obtained drug production registration approvals from China's National Medical Products Administration for Oseltamivir Phosphate Capsules (30mg, 45mg, and 75mg). Classified as a chemical drug category 4, these approvals are considered to have passed the consistency evaluation. This product is primarily used for the treatment of influenza A and B in adults and children aged 1 year and above, as well as for the prevention of influenza A and B in adults and adolescents aged 13 years and above.
The group is the second domestic enterprise to be the first to obtain a drug production registration approval for Drotaverine Hydrochloride Tablets (40mg). Classified as a chemical drug category 3, this approval is also considered to have passed the consistency evaluation. This product is mainly used for smooth muscle spasms related to biliary tract and urinary system diseases, as well as for the auxiliary treatment of smooth muscle spasms caused by gastrointestinal diseases and dysmenorrhea. The group's Drotaverine Hydrochloride active pharmaceutical ingredient has been approved by the National Medical Products Administration for registration as an active ingredient used in marketed preparations.
The group is the second domestic enterprise to be the first to obtain a drug production registration approval for Metoclopramide Tablets (10mg). Classified as a chemical drug category 3, this approval is considered to have passed the consistency evaluation. This product is primarily used for the symptomatic treatment of nausea and vomiting caused by various etiologies, short-term treatment of symptomatic gastroesophageal reflux that is ineffective with conventional therapy, and relief of symptoms of acute and recurrent diabetic gastroparesis. The group's Metoclopramide active pharmaceutical ingredient has been approved by the National Medical Products Administration for registration as an active ingredient used in marketed preparations.
Comments